Please try another search
Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also develops TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. Toleranzia AB was incorporated in 2011 and is headquartered in Gothenburg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Anders Milton | 74 | 2018 | Chairman of the Board |
Ann-Charlotte Rosendahl | 58 | 2020 | Chair of the Board |
Charlotte Fribert | 56 | 2016 | CEO & Executive Director |
Kristian Sandberg | 62 | 2017 | Director |
Eva Lindgren | 73 | 2018 | Director |
Maarten Kraan | 62 | 2018 | Director |
Thomas Eldered | 63 | 2021 | Director |
Jan P. Mattsson | 59 | 2020 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review